NeoGenomics, Inc. (NASDAQ:NEO) Receives Consensus Rating of “Moderate Buy” from Analysts

NeoGenomics, Inc. (NASDAQ:NEO) has been given a consensus recommendation of “Moderate Buy” by the ten analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $19.89.

A number of brokerages have recently weighed in on NEO. Craig Hallum initiated coverage on shares of NeoGenomics in a research report on Wednesday, May 1st. They set a “buy” rating and a $26.00 price target on the stock. TD Cowen decreased their target price on NeoGenomics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Stephens restated an “overweight” rating and issued a $19.00 price target on shares of NeoGenomics in a report on Tuesday, July 30th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price objective on shares of NeoGenomics in a report on Tuesday, July 30th. Finally, Benchmark reissued a “buy” rating and set a $18.00 target price on shares of NeoGenomics in a research note on Tuesday, July 30th.

NeoGenomics Trading Down 0.4 %

NASDAQ NEO opened at $16.33 on Thursday. NeoGenomics has a 12 month low of $11.03 and a 12 month high of $21.22. The stock has a 50-day simple moving average of $15.19 and a 200 day simple moving average of $14.87. The company has a current ratio of 2.01, a quick ratio of 7.22 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $2.09 billion, a PE ratio of -24.74 and a beta of 1.18.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Monday, July 29th. The medical research company reported $0.03 earnings per share for the quarter. The business had revenue of $164.50 million for the quarter, compared to the consensus estimate of $161.82 million. NeoGenomics had a negative net margin of 12.50% and a negative return on equity of 2.72%. NeoGenomics’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same period last year, the company posted ($0.09) EPS. Research analysts forecast that NeoGenomics will post -0.19 EPS for the current year.

Institutional Trading of NeoGenomics

A number of hedge funds and other institutional investors have recently made changes to their positions in NEO. Louisiana State Employees Retirement System bought a new position in NeoGenomics in the fourth quarter valued at $1,032,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of NeoGenomics by 19.7% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,707 shares of the medical research company’s stock valued at $497,000 after acquiring an additional 5,064 shares during the last quarter. Handelsbanken Fonder AB raised its holdings in NeoGenomics by 7.0% during the fourth quarter. Handelsbanken Fonder AB now owns 19,900 shares of the medical research company’s stock worth $322,000 after acquiring an additional 1,300 shares in the last quarter. Jennison Associates LLC raised its holdings in NeoGenomics by 17.8% during the fourth quarter. Jennison Associates LLC now owns 591,556 shares of the medical research company’s stock worth $9,571,000 after acquiring an additional 89,473 shares in the last quarter. Finally, Yousif Capital Management LLC boosted its position in NeoGenomics by 2.6% during the fourth quarter. Yousif Capital Management LLC now owns 65,447 shares of the medical research company’s stock valued at $1,059,000 after purchasing an additional 1,654 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.